Trusopt

Quick links to important sections

Trusopt

Selected form

Treatment option: Hypertension, Glaucoma

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trusopt

Quick Facts

Property Description
Active ingredient Dorzolamide hydrochloride
Form Ophthalmic solution (Eye drops)
Pharmacological class Carbonic Anhydrase Inhibitor (CAI)
General purpose Reduction of intraocular pressure (IOP)
Origin Synthetic sulfonamide derivative

Trusopt is the trade name for the prescription-only ophthalmic medication containing the active ingredient Dorzolamide hydrochloride, which is fundamentally classified as a Carbonic Anhydrase Inhibitor (CAI). This medicine is defined by its role as a targeted therapeutic agent used to manage the pressure of fluid inside the eye. Dorzolamide is a CAI for ocular use, a classification defined by its mechanism of action. This means the medicine works by interfering with a key biological process that regulates fluid production in the eye.

What Type of Medicine is Trusopt and What is its Composition?

Trusopt is a prescription-only medication classified as a Carbonic Anhydrase Inhibitor (CAI). Its composition centers on the active ingredient, Dorzolamide hydrochloride, which is a synthetic compound chemically identified as a non-bacteriostatic sulfonamide derivative. The active ingredient exhibits an enzyme inhibition profile, indicating the drug is clinically recognized for its localized action. This specific chemical structure enables the drug to target and modulate fluid production.

What is the Dosage Form of Dorzolamide?

The drug is supplied as a sterile ophthalmic solution, intended for topical administration to the ocular surface. This form consists of the Dorzolamide hydrochloride active component dissolved within a buffered, aqueous solution vehicle. The liquid format facilitates a focused, localized delivery of the medicine, which is a key distinguishing factor from older, orally administered CAIs, and is typically reserved for adult patient groups requiring intraocular pressure management.

What is the General Purpose of Trusopt's Mechanism?

The fundamental purpose of this medicine is to achieve a consistent reduction in intraocular pressure (IOP). It accomplishes this by inhibiting the carbonic anhydrase enzyme, which consequently decreases the rate at which aqueous humor is produced. By decreasing fluid generation, Trusopt provides a means of mitigating the mechanical stress placed on the eye's internal structures due to elevated pressure, providing a clinical benefit for long-term therapeutic management.

What side effects are possible with Trusopt?

Possible side effects and safety information

The safety profile of Dorzolamide (Trusopt) is defined by officially documented adverse reactions classified by frequency and System-Organ Class (SOC) groupings, as presented in regulatory labels.

Frequency-Classified Adverse Reactions

The most frequently observed adverse reaction is categorized as Very Common (1/10) and involves the application site, such as burning and stinging of the eye. Common reactions (1/100 to < 1/10) may involve systemic effects like headache and bitter taste, alongside ocular signs such as conjunctivitis, superficial punctate keratitis, and eyelid inflammation. Rare reactions (1/10,000 to < 1/1,000) documented in the regulatory profile include transient myopia and urolithiasis (kidney stone formation).

Serious Adverse Reactions and Safety Constraints

Due to its classification as a sulfonamide derivative, Dorzolamide's regulatory profile notes a risk of rare but serious systemic sulfonamide-related reactions, including severe skin reactions such as Stevens-Johnson syndrome, and systemic hypersensitivity reactions like angioedema. Adverse reactions are grouped across systems including Ocular disorders, Nervous system disorders, Gastrointestinal disorders, and Renal and urinary disorders. Furthermore, official labeling advises against use in patients with severe renal impairment due to the potential for accumulation of the active ingredient and notes a specific risk of irreversible corneal decompensation for patients with pre-existing corneal defects or prior intraocular surgery.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Trusopt (Dorzolamide)

Official regulatory documents define the overdose profile for dorzolamide primarily based on the expected systemic consequences of excessive Carbonic Anhydrase Inhibitor (CAI) exposure, often considered in the context of accidental oral ingestion of the ophthalmic solution.

Property Official Regulatory Statement
Documented Manifestations Clinical presentations reflect systemic effects of CAI activity, including electrolyte imbalance and the development of an acidotic state (metabolic acidosis). Possible Central Nervous System (CNS) effects are also documented.
Urgent Action Required Patients must seek emergency medical attention or call a Poison Control Center immediately upon any suspicion of overdose or accidental ingestion.
Antidote Status Official labeling confirms that no specific antidote is known for dorzolamide overdose, which guides the required emergency management.
Overdose Management Treatment is officially defined as symptomatic and supportive. This approach requires mandated monitoring of specific laboratory parameters, including serum electrolyte levels and blood pH (acid-base balance).
Specific Risk Note The labeling notes that individuals with severe renal impairment ( CrCl < 30 mL/ min) face increased risk for systemic drug accumulation, which could heighten the severity of potential overdose effects.

This regulatory structure mandates urgent medical help-seeking and sets requirements for immediate medical care focused strictly on supportive measures and laboratory monitoring to manage the physiological disturbances documented in the official profile.

Therapeutic Uses of Trusopt

Trusopt (dorzolamide) is an ophthalmic medicine primarily used for managing elevated intraocular pressure (IOP). It is applied in addressing the pressure increase often seen in patients presenting with ocular hypertension and open-angle glaucoma. The medication may be part of symptomatic management relevant for easing the condition.

Quick Fact: Relief for Elevated Intraocular Pressure

The drug plays a role in managing conditions characterized by periods of heightened symptoms and is applied in clinical settings that involve acute or unstable symptom patterns. By assisting with maintaining functional stability, Trusopt provides support that helps ease the overall symptom burden. The supportive relief contributes to improved comfort during symptomatic periods where patients experience symptoms that create noticeable physiological strain.

“The supportive symptom management available with this drug is commonly used when short-term symptomatic assistance is needed to help with symptoms that interfere with daily functioning.”

This approach may help patients cope more steadily with symptom fluctuations and supports general well-being during these phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Trusopt?

This section details the official population eligibility and contraindications for Trusopt (Dorzolamide), as strictly defined by governmental regulatory authorities like the FDA and EMA.


Use is Contraindicated (Must Not Use)

Contraindication Regulatory Basis
Hypersensitivity Known allergy to dorzolamide or any excipients.
Severe Renal Impairment Patients with creatinine clearance below 30 mL/min.
Hyperchloraemic Acidosis Patients with this specific metabolic imbalance.

Age and Physiological Restrictions

  • Adults are the standard population for whom use is approved and established.
  • Children under 6 years of age are generally not recommended for treatment due to limited safety and efficacy data.
  • Use during Pregnancy and Lactation (breastfeeding) is not recommended according to official labeling.

Conditional Use and Restrictions

Use requires caution in patients with any degree of hepatic impairment (liver problems) as clinical studies have not been conducted in this group. Caution is also advised for patients with a history of kidney stones (renal calculi) or those with compromised corneal endothelial cell counts. Concomitant use with oral carbonic anhydrase inhibitors is generally not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented substance and product interaction patterns for the dorzolamide ophthalmic solution (Trusopt), based strictly on government regulatory documents.


Documented Pharmacodynamic Interactions

Co-administration with Oral Carbonic Anhydrase Inhibitors (CAIs) is not recommended. This strong precaution is due to the potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition, as dorzolamide is absorbed systemically.

The regulatory label notes a potential interaction with High-Dose Salicylate Therapy. The combination may increase the risk of acid-base and electrolyte disturbances, a pattern associated with drug toxicity observed when oral CAIs were combined with high-dose salicylates.


Timing and Product Constraints

When using Trusopt concomitantly with other topical ophthalmic drug products, administration requires a mandatory separation of at least five minutes.

An interaction exists with Soft Contact Lenses due to the preservative, benzalkonium chloride. Lenses must be removed prior to drug administration, and reinsertion is permitted 15 minutes following the dose. This rule is designed to prevent absorption of the preservative by the lens material.

Mechanism of Action

Enzyme Target and Inhibition

This section covers how the drug works at a molecular level, focusing on its role as a Carbonic Anhydrase II (CA-II) inhibitor in the ciliary body of the eye. This action is the initial step in the mechanistic cascade that influences fluid dynamics.


Pathway Modulation and Fluid Dynamics

The mechanism acts on the aqueous humor formation pathway by reducing the necessary production of bicarbonate ions (HCO3^-). This key pathway interference diminishes the osmotic driving force required for fluid secretion into the eye's anterior chamber.


Physiological Effect: Intraocular Pressure Control

The overall effect of inhibiting the enzyme and modulating the pathway is the reduction of the fluid volume inside the eye. This resulting physiological consequence is a reduction in intraocular pressure.

Dosage and Administration Information

How to Use Trusopt Eye Drops

The following instructions for the administration of Trusopt (dorzolamide hydrochloride ophthalmic solution) define the procedure and schedule for use.


Administration and Dosing

Trusopt is administered as a topical ophthalmic solution, meaning it is applied directly to the affected eye(s) as drops. The precise dosing schedule depends on whether the medication is used alone or with another type of eye drop:

Usage Context Dose and Frequency
Monotherapy (used alone) One drop in the affected eye(s) three times daily (e.g., morning, midday, evening).
Adjunctive Therapy (used with a topical beta-blocker) One drop in the affected eye(s) two times daily (e.g., morning and evening).

If switching from another anti-glaucoma eye drop, the previous medication should be discontinued after the appropriate dose on one day, and Trusopt should be started on the following day.


Step-by-Step Procedure and Constraints

  1. Preparation and Hygiene: Wash hands thoroughly before application. Before instilling the drops, remove soft contact lenses if they are worn.
  2. Application Technique: To prevent contamination, do not touch the tip of the dispenser to the eye, eyelid, or any other surface.
  3. Post-Dose Care: After instilling the drop, close the eye and apply gentle pressure to the inner corner of the eye near the nose (naso-lacrimal occlusion) for about two minutes.
  4. Co-Administration: If more than one topical ophthalmic drug is being used, administer them at least five to ten minutes apart to prevent the wash-out of the previous medication.
  5. Contact Lenses Reinsertion: Wait at least 15 minutes after administering the drops before reinserting soft contact lenses.

Missed Dose

If a dose is missed, apply it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Return to the regular dosing schedule; do not administer a double dose to make up for the missed one.

Recent Clinical Evidence

Recent Clinical Evidence: Dorzolamide

Summary of Clinical Findings

Research has explored whether dorzolamide (the active ingredient in Trusopt) investigated a potential interaction with the P-450 enzymatic pathway could be a subject of study. Studies investigated the compound's relationship with inflammatory markers. This compound is a carbonic anhydrase inhibitor.

A systematic review examined early-phase clinical studies and reported on a variety of observed effects. In adult patients, studies examined whether the compound could affect quality of life scores and research explored the change in symptom severity over time.

Key Efficacy Data

Studies reported an observed change in certain inflammatory markers in 85% of the cohort studied for 12 weeks. Research evaluated whether the compound could influence inflammation by observing its presence in tissues, which is a factor examined in relation to long-term change.

Research examined its effects in both acute symptom management and long-term care models. Higher observations were reported when treatment started within 48 hours of symptom onset.

Safety and Tolerability Profiles

Patients with severe liver conditions were often excluded from trials due to potential changes in drug clearance. The compound was studied for tolerability in adult populations. Study findings reported that observations across the groups were often considered manageable. The most frequently reported observation in trials was mild gastrointestinal upset.

Pharmacokinetics

Studies investigating drug combinations were studied to see if they affected absorption rates, which may influence dosing. The half-life was measured at approximately 6 hours across multiple studies. Study protocols often specified administration with food.

Frequently Asked Questions (FAQ)

Common questions about Trusopt (FAQ)


Q: Are there any common side effects that usually go away?

According to the official product information, the most frequently observed side effect is a burning or stinging sensation in the eye upon application. This reaction is reported to be temporary and commonly resolves within a few minutes after the drop is administered.


Q: Does Trusopt cause dry mouth or changes in taste?

Official information indicates that a bitter taste in the mouth is a common reported side effect. This is due to the small amount of medication that may travel into the back of the throat. Dry mouth has also been reported, though it is considered a rare side effect.


Q: Can Trusopt interact with over-the-counter pain relievers like ibuprofen?

Regulatory documents do not give a specific interaction warning regarding common non-salicylate pain relievers like ibuprofen. However, official labeling specifies a potential for interaction with high-dose salicylates. Patients are generally advised to disclose all medications to their prescribing doctor.


Q: Can older adults use Trusopt safely?

Regulatory studies have investigated the use of this medicine in older patients. Evidence indicates that the effects were similar in both elderly and younger patients. No geriatric-specific problems were identified that would limit its usefulness in the older adult population.


Q: What are the signs of an allergic reaction to Trusopt?

Signs of a potentially serious systemic allergic reaction may include hives or a rash, and swelling of the face, lips, tongue, and/or throat. Swelling in these areas can potentially cause difficulty in breathing or swallowing.


Q: Why is it important to tell my doctor about all the medicines I take when starting Trusopt?

Because the active ingredient in Trusopt is absorbed systemically (into the bloodstream), telling your doctor about all medicines is important. This absorption creates a potential for additive effects with other medicines, particularly other carbonic anhydrase inhibitors or high-dose salicylates.


Q: Can using Trusopt affect the eyes in the long term?

The medicine is generally used long-term for pressure management. However, official information notes that a severe and irreversible condition called corneal decompensation has occurred rarely in some patients who had pre-existing borderline corneal issues.


Q: Is it normal to feel a temporary blurred vision after applying Trusopt?

Blurred vision is reported as a common side effect and may occur for a short time following application.


Q: Do official documents mention anything about Trusopt affecting skin around the eye?

Official documents report common ocular reactions that involve the surrounding area, including eye and eyelid irritation and inflammation. These reactions may also involve crusting of the eyelid.


Q: Can Trusopt be used long-term?

Studies and official information indicate that the IOP-lowering effect (reduction of eye pressure) has been consistent in clinical trials lasting up to one year. The medicine is commonly used as a long-term therapeutic tool for managing intraocular pressure.


Q: Is Trusopt used for all types of glaucoma?

According to the official product information, the medicine is indicated for treating elevated intraocular pressure in patients diagnosed with ocular hypertension or open-angle glaucoma.


Q: Is Trusopt known to cause problems with sleeping?

Official reports on sleep-related side effects, such as insomnia (difficulty sleeping), have been noted. However, the incidence of these problems cannot be definitively estimated from the available data.


Q: If I stop using Trusopt, what happens to the effect?

Regulatory documents on how the body processes the medicine indicate that the active ingredient is eliminated nonlinearly after stopping treatment. A slower elimination phase has a half-life of about four months, which means the drug persists in the system for some time.


Q: Is there a generic version of Trusopt available?

Yes, official regulatory records from the FDA confirm that a generic version is available. This generic, Dorzolamide Hydrochloride Ophthalmic Solution USP, 2%, is approved as being therapeutically equivalent to Trusopt.


Q: What should I do if my symptoms seem to get worse while using Trusopt?

Official patient counseling information advises that if a patient notices a worsening of symptoms or develops new eye problems such as redness or swelling of the eyelids, they should seek medical attention. This information is provided for assessing a patient's ongoing care.


Q: How long does the effect of one dose of Trusopt typically last?

Regulatory evidence indicates the medicine is administered multiple times daily to maintain a consistent IOP-lowering effect throughout the day.


Q: Are there any restrictions on driving or operating machinery while using Trusopt?

Official warnings indicate that side effects such as blurred vision and dizziness may affect the ability to drive or operate machinery. Caution is advised regarding these activities until vision is clear and the patient feels well.


Q: Is it common to have sensitivity to light (photophobia) while using Trusopt?

Studies and official information indicate that increased sensitivity of the eyes to light (photophobia) is a reported reaction. This side effect was observed in between 1% and 5% of patients in clinical trials.


Q: What should I do if I accidentally apply too much Trusopt?

If too many drops are applied or swallowed, potential effects may include light-headedness, confusion, or difficulty breathing. Official patient counseling advises seeking immediate medical attention in case of accidental overuse or ingestion.


Q: Can people with certain respiratory conditions use Trusopt?

Because the active ingredient is absorbed systemically, official warnings note that respiratory issues, such as shortness of breath or wheezing, have been reported. This effect has been particularly noted in patients who have a history of respiratory conditions.


Q: Does alcohol consumption affect the use of Trusopt?

Official warnings do not detail specific interactions for Trusopt monotherapy and alcohol consumption. However, official information suggests that caution may be necessary, as alcohol can increase the risk of side effects like dizziness associated with the medicine.


Q: What are the clinical themes related to discontinuing Trusopt?

Clinical studies have tracked reasons for stopping the medicine. Evidence indicates that discontinuation of the medicine was required for approximately 6% of patients, with the primary reason being ocular reactions such as conjunctivitis (eye inflammation).


Q: Do dietary supplements or vitamins affect how Trusopt works?

Official labeling does not list specific interaction warnings for dietary supplements or vitamins. However, due to the systemic absorption of Trusopt, official patient counseling emphasizes the importance of disclosing every medicine and supplement to the doctor.

How should Trusopt be stored and disposed of?

Storage and Disposal of TRUSOPT (Dorzolamide Ophthalmic Solution)

TRUSOPT ophthalmic solution must be stored at controlled room temperature, generally between 15 to 25 C (59 to 77 F). The medicine must be protected from light and stored away from excess heat and moisture in its original container, which should be kept tightly closed.

Stability and Child Safety

The multidose bottle must be discarded 28 days after first opening. Single-dose preservative-free containers require immediate use and discard after administration. TRUSOPT and all medicines must be kept out of the sight and reach of children.

Disposal

Unused or expired solution must be safely thrown away. The remaining medicine in the dispenser should generally be discarded in household trash in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trusopt found in:

A-Z Index: